Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase III Trial of RP 5063 in Patients with Schizophrenia

Next Previous
Trial Profile

A Pivotal Phase III Trial of RP 5063 in Patients with Schizophrenia

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 29 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brilaroxazine (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms REVEAL

Most Recent Events

  • 26 Jun 2023 According to a Reviva Pharmaceuticals media release, topline data from pivotal Phase 3 REVEAL study in schizophrenia will be presented in the third quarter of 2023.
  • 04 May 2023 According to a Reviva Pharmaceuticals media release, U.S. Food and Drug Administration (FDA) has agreed to consider a potential superior safety label claim if there is a positive outcome on a relevant endpoint in this trial.
  • 10 Jan 2022 According to a Reviva Pharmaceuticals media release, the company plans to initiate this trial by the end of January 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top